Patient Name:	N	MRN: S						Study Identifier:					
	Baseline Scan Date:												
New RECIST V 1.1  Measurable Lesions  Longest diameter ≥ 10 mm  Lymph nodes ≥ 15 mm in short  ** All lesions recorded as target	w RECIST V 1.1 <u>surable Lesions</u> est diameter ≥ 10 mm  Target Lesions All measurable lesions up to a						Non- Target Lesions All lesions or sites of disease not identified as target lesions should be identified & followed as 'present', 'absent', or 'unequivocal progression' - small lesions with longest diameter > 10 mm - pathological lymph nodes w/ short axis 10 to <15 mm - all non-measurable lesions						
possible, even when very small. <b>Date of Evaluation</b>	mm/dd/yyyy mm/dd/yyyy				mm/dd/yyyy mm/dd/yyyy mm/dd/yyyy					1			
								<u> </u>		<u> </u>			
Target Lesions	:	*Instruct						nillimete easureme			s (mm)		
Description	Imaging Modality	Slice	*	Slice	*	Slice	*	Slice	*	Slice	*		
1.													
2.													
3.													
4.													
5.													
Total / % change from screening/nadir  Date used for Comparison		mm%		mm%				mm%		mm%			
Non-Target Lesions	*Instructio			esent),	A (abse	nt), <b>U</b> (	Unequiv			1)			
Description	Imaging Modality	Slice	*	Slice	*	Slice	*	Slice	*	Slice	*		
1.													
2.													
3.													
4.													
5.													
New Lesions	*Instruction							(mm) t in millir	neters (	mm)			
Description	Imaging Modality	Slice	*	Slice	*	Slice	*	Slice	*	Slice	*		
Comments:			<u> </u>	I	<u>I</u>		1		<u> </u>				
Response: CR = Complete Response; PR = Partial Response SD = Stable Disease; PD = Progressive Disease		CR		CR		CR		CR   PR   SD   PD		CR			
Immune Response:													
						1							
Reviewed By Investigator (sign & date)													